The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...

-The Hindu     Jagdalpur Jail Superintendent says that a psychiatrist asked her questions about "anger" The Chhattisgarh government has initiated an enquiry into the mental health of Adivasi teacher Soni Sori lodged in the Jagdalpur jail to ascertain whether she should be sent to the mental asylum in Agra, according to women's rights groups. A legal team visiting Ms. Sori on March 15 after she failed to appear for a hearing the previous day,...

-The Hindu     Protesters see attempt by EU to undermine Indian judiciary in the EU-FTA pact People living with HIV, cancer patient groups and public health activists came out on the streets on Wednesday demanding that India reject the European Union's demands in the European Union-India Free Trade Agreement (EU-India FTA) negotiations. The protests coincide with Prime Minister Manmohan Singh's visit to Germany to meet Chancellor Angela Merkel with the FTA on top of...

-Live Mint Tariffs reach at least Rs.4 per unit in many states, finds analysis, amid efforts to bail out state discoms Indian domestic consumers in 16 states are paying at least `4 per unit for power and in some cases even more, according to an analysis, thus giving the lie to the long-held axiom that raising tariffs is nearly impossible in India given the political compulsions. The finding also shows conclusively that...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...